Personalized Treatment for Endometrial Carcinoma Comparing Chemotherapy, Chemoradiotherapy, and Radiotherapy by Molecular Subtypes

What this Trial Is About

Researchers are evaluating different adjuvant therapies for women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. This trial focuses on comparing treatments based on specific molecular subgroups of the cancer, including p53 abnormal, mismatch repair deficient (MMR-D), and no specific molecular profile (NSMP). The goal is to improve treatment personalization by understanding how these molecular subtypes respond to therapies and to reduce over- or undertreatment while improving patient outcomes and quality of life. The trial compares chemotherapy alone versus chemoradiotherapy for women with p53 abnormal and nonendometrioid carcinoma subtypes. Chemotherapy involves paclitaxel and carboplatin every three weeks for six cycles, while chemoradiotherapy adds whole pelvic radiotherapy over 5 to 6 weeks after chemotherapy. For women with MMR-D and NSMP molecular subgroups, vaginal brachytherapy is compared to whole pelvic radiotherapy, with specific radiation doses and schedules defined for each treatment. Participants will be followed for at least five years to monitor for cancer recurrence, survival, adverse events, and patient-reported symptoms and quality of life. Assessments include tracking the location and timing of any cancer reappearance, overall survival, and recurrence-free survival. Women who consent to follow-up but not randomization will receive standard treatment and be monitored as part of the study. The entire study period involves long-term follow-up to evaluate outcomes and safety.

PErsonalized TReatment for Endometrial Carcinoma